MMF
MMF is a pharmaceutical drug with 32 clinical trials. Currently 6 active trials ongoing. Historical success rate of 84.2%.
Success Metrics
Based on 16 completed trials
Phase Distribution
Phase Distribution
5
Early Stage
10
Mid Stage
13
Late Stage
Highest Phase Reached
Phase 4Trial Status & Enrollment
80.0%
16 of 20 finished
20.0%
4 ended early
6
trials recruiting
32
all time
Detailed Status
Development Timeline
Analytics
Development Status
Trials by Phase
Trials by Status
Recent Activity
Optimization of NULOJIX® Usage As A Means of Avoiding CNI and Steroids in Renal Transplantation
Sirolimus+Ruxolitinib+Mycophenolate Mofetil for Prophylaxis of aGVHD in Patients Receiving Haplo-HSCT Who Are Intolerant to CNI
A Study to Evaluate the Efficacy and Safety of Obinutuzumab in Participants With ISN/RPS 2003 Class III or IV Lupus Nephritis
Belimumab and Rituximab Combination Therapy for the Treatment of Diffuse Cutaneous Systemic Sclerosis
Allogeneic Hematopoietic Cell Transplantation for Disorders of T-cell Proliferation and/or Dysregulation
Clinical Trials (32)
Optimization of NULOJIX® Usage As A Means of Avoiding CNI and Steroids in Renal Transplantation
Sirolimus+Ruxolitinib+Mycophenolate Mofetil for Prophylaxis of aGVHD in Patients Receiving Haplo-HSCT Who Are Intolerant to CNI
A Study to Evaluate the Efficacy and Safety of Obinutuzumab in Participants With ISN/RPS 2003 Class III or IV Lupus Nephritis
Belimumab and Rituximab Combination Therapy for the Treatment of Diffuse Cutaneous Systemic Sclerosis
Allogeneic Hematopoietic Cell Transplantation for Disorders of T-cell Proliferation and/or Dysregulation
A Study to Evaluate the Efficacy and Safety of Obinutuzumab Versus MMF in Participants With Childhood Onset Idiopathic Nephrotic Syndrome
UCB Transplant for Hematological Diseases Using a Non Myeloablative Prep
A Study of TCD601 in the Induction of Tolerance in de Novo Liver Transplantation
Sirolimus+Abatacept+Mycophenolate Mofetil for Prophylaxis of aGVHD in Patients Receiving Haplo-HSCT Who Are Intolerant to Calcineurin Inhibitors
Allo HSCT Using RIC for Hematological Diseases
Comparison of Mycophenolate Mofetil and Cyclophosphamide for Active Takayasu's Arteritis
Mycophenolate Mofetil in Gastrointestinal Henoch-Schonlein Purpura
Drug-Drug Interaction (DDI) Study of ALXN2050 in Healthy Adult Participants
KidneyCare Immuno-optimization in Renal Allografts (KIRA)
Use of Baricitenib to Maintain of Remission
REduCing Immunogenicity to PegloticasE (RECIPE) Study
Sirolimus & Mycophenolate Mofetil as GVHD Prophylaxis in Myeloablative, Matched Related Donor HCT
Combination Therapy of Severe Aplastic Anemia
Natural Killer Cells Reconstitution Kinetics Post Haploidentical Transplantation
ATG in HLA-matched Sibling HSCT as GVHD Prophylaxis
Drug Details
- Intervention Type
- DRUG
- Total Trials
- 32